Who Owned Stephen Ray’s Science? The Lydac Neuroscience Connection
The Men Behind Wellbeing — Chapter Six
The patent trail has taken this investigation beyond Wellbeing International Foundation and Natural Biosciences. Official records identify another company associated with Stephen Ray’s microvesicle intellectual property: Lydac Neuroscience Limited. Who was behind it, what did it control, and what happened to the technology afterwards?
Investigations change when documents replace assumptions.
In the previous chapter, we established something important.
There is a genuine patent history associated with Stephen Ray and microvesicle technology.
The intellectual-property trail reaches back to British priority applications filed in 2008.
But the records revealed something else.
The company appearing alongside Ray in the early patent history was not Wellbeing International Foundation.
It was not Natural Biosciences SA.
It was:
Lydac Neuroscience Limited.
That discovery changes the direction of this investigation.
Because if we want to understand who owns—or historically owned—the science behind technology now associated with Cell-Free Therapy, Lydac can no longer be ignored.
Lydac Neuroscience Appears Directly in the Patent Record
The US patent application titled “Microvesicles” identifies:
Inventor: Stephen Ray — Bath, Great Britain
and:
Applicant: Lydac Neuroscience Limited — Bath, Great Britain.
That is stronger evidence than a biography, interview or promotional article.
It places Lydac directly within the intellectual-property history.
The application belongs to the patent family whose priority claims reach back to two British filings:
GB 0800107.5 — 4 January 2008
and:
GB 0804932.2 — 17 March 2008.
The international application followed in January 2009.
This means Lydac was associated with the technology during a very early stage of its documented commercial development.
The Canadian Patent Record Goes Further
An official Canadian Intellectual Property Office publication provides additional evidence.
The record identifies Stephen Ray as inventor and Lydac Neuroscience Limited as proprietor or assignee in connection with the same broader international patent family.
This distinction is important.
Stephen Ray was the inventor.
Lydac appears as a corporate rights holder.
Those are not the same thing.
And understanding the difference is essential if we are going to follow the ownership of the science properly.
Inventing Technology Does Not Necessarily Mean Owning It
Patent law separates inventorship from ownership.
A scientist can invent something without personally controlling its commercial exploitation.
An employer may own an employee's invention.
An inventor can assign rights to a company.
A company can purchase patents.
A patent can be licensed.
Rights can move between companies.
They can also become assets in an insolvency, acquisition or corporate restructuring.
Therefore, the fact that Stephen Ray is named as inventor does not automatically mean he personally owned the technology.
The records instead tell us that Lydac Neuroscience Limited had a documented legal relationship with this patent family.
That raises the next obvious question:
What exactly was Lydac Neuroscience Limited?
The Company Behind the Patent
This is where the investigation needs to move from patent databases into corporate records.
We need to reconstruct Lydac itself.
When was it incorporated?
Where was it incorporated?
Who founded it?
Who were its directors?
Who were its shareholders?
Was Stephen Ray a director?
Did he own shares?
Who funded the company?
What other intellectual property did it possess?
Did it have employees?
Did it conduct laboratory research?
Did it raise outside investment?
Did it generate revenue?
And eventually:
What happened to it?
These are not peripheral questions.
If Lydac controlled technology that later became commercially important elsewhere, the fate of the company may help establish the fate of its intellectual property.
Natural Biosciences Remains Part of the Story
Lydac's appearance does not remove Natural Biosciences SA from this investigation.
Historical evidence separately connects Stephen Ray with Natural Biosciences.
A South African publication discussing stem-cell research identified:
“Dr Stephen Ray, chief scientist at Natural Biosciences SA.”
It also associated him with Oxford Brookes University and discussed regenerative applications involving adipose-derived cells.
The article went further.
It described Natural Biosciences as a company involved in stem-cell research and treatment and referred to patients reportedly receiving treatment in Germany and Switzerland.
That is potentially important.
But we now have to resist the temptation to connect corporate dots that the documents have not yet connected for us.
Lydac and Natural Biosciences Are Not Yet a Proven Corporate Chain
At present, we have two separate propositions supported by different evidence.
Lydac Neuroscience Limited appears in the patent records associated with Stephen Ray's microvesicle technology.
And:
Natural Biosciences SA appears in historical material associated with Stephen Ray's stem-cell research and treatment activity.
Those facts do not automatically establish that Natural Biosciences acquired Lydac.
They do not establish that Lydac licensed its technology to Natural Biosciences.
They do not establish common ownership.
They do not establish that one company replaced the other.
They may have been closely connected.
They may have operated alongside one another.
Ray may simply have worked with both.
The relationship needs to be proven.
That means we need another type of document.
The Missing Evidence Is the Ownership Transfer
If technology moved from one company to another, there should normally have been some legal mechanism behind that movement.
Possibilities include:
an assignment;
a licence;
an acquisition;
an asset sale;
a corporate restructuring;
or another contractual arrangement.
This is now one of the most important targets in the investigation.
Stage One: The Inventor
Stephen Ray is named as inventor on the microvesicle patent family.
That is documented.
Stage Two: The Early Corporate Rights Holder
Lydac Neuroscience Limited appears as applicant in the US record and proprietor or assignee in the Canadian patent publication.
That is also documented.
Stage Three: Natural Biosciences
Historical material independently associates Stephen Ray with Natural Biosciences SA and regenerative/stem-cell research.
Stage Four: Wellbeing International Foundation
Today, Wellbeing presents Ray's scientific history as central to the development of its Cell-Free Therapy.
What we do not yet have is the complete legal bridge connecting all four stages.
That distinction is critical.
Stephen Ray’s Patent History Extends Beyond Microvesicles
The investigation has also identified additional biological intellectual property carrying Stephen Ray's name.
Patent databases list applications involving RNA, including:
“Method Of Genotypically Modifying Cells By Administration Of RNA.”
That application identifies Stephen Ray and Michael Fischer as inventors and Fischer Education Project Limited as applicant.
This potentially pushes Ray's commercial intellectual-property history even further backwards.
It also introduces yet another corporate name.
Fischer Education Project Limited.
Again, we should not assume that every company appearing alongside Ray formed part of one continuous enterprise.
But the pattern is increasingly clear.
Ray's involvement in commercial biological intellectual property predates Wellbeing by many years.
The Scientific History Is Longer Than the Wellbeing Brand
This matters because a reader encountering Wellbeing today could reasonably assume that Cell-Free Therapy is primarily a product of the modern Wellbeing organisation.
The historical record suggests a much longer development story.
We now have evidence involving:
RNA-related intellectual property;
microvesicle patents;
Lydac Neuroscience Limited;
Natural Biosciences SA;
reported treatment activity in Europe;
the later partnership with Andrew Chancellor;
and eventually Wellbeing International Foundation.
That does not mean each organisation was delivering the same product.
It does not establish uninterrupted ownership.
It does not establish that the 2008 technology is identical to today's Cell-Free Therapy.
But it does establish that the scientific and commercial history surrounding Ray is considerably older than the present brand.
Patients Were Reportedly Being Treated by 2011
The historical Natural Biosciences material creates another important question.
The South African publication describes treatment activity involving patients in Germany and Switzerland.
If those reports are accurate, then patient treatment associated with Ray's broader scientific work may have been occurring around fifteen years ago.
That potentially gives us a substantial historical period from which clinical evidence might exist.
So where is it?
Where Is the Long-Term Clinical Dataset?
If related biological interventions have been administered to patients for many years, there should potentially be an extensive body of observational information.
How many patients were treated?
What conditions did they have?
What exactly did they receive?
What dosages were used?
What outcomes were measured?
How long were patients followed?
How many failed to improve?
How many deteriorated?
What adverse events occurred?
Were all outcomes recorded—or primarily successful cases?
Were the results ever independently analysed?
And where are those data today?
These questions become particularly interesting when compared with Wellbeing's recent peer-reviewed longevity pilot.
That study was real and peer reviewed.
But only fourteen participants completed it, and every participant received multiple simultaneous interventions, preventing the study from isolating the effect of Cell-Free Therapy.
If a treatment lineage really extends back more than a decade, the obvious question is:
Why is the publicly available controlled human evidence still so limited?
Andrew Chancellor Enters an Existing Scientific Story
This also changes how we should view Andrew Chancellor's arrival.
Chancellor has publicly described meeting Stephen Ray and eventually discussing how Ray's research could be commercialised.
But the patent evidence establishes that Ray's intellectual-property activity existed years earlier.
Therefore Chancellor does not appear to have entered the story at the beginning of the science.
He entered an existing scientific and intellectual-property history.
That creates a more precise question:
What existed when Chancellor arrived?
Was Lydac still active?
Was Natural Biosciences operating?
Who owned the relevant patents?
What rights did Ray personally control?
Were investors already involved?
And what exactly did Chancellor subsequently commercialise?
Did Chancellor Acquire, License or Build Around Existing Technology?
This is now one of the most important commercial questions.
Chancellor brought extensive business experience.
Ray brought scientific history and intellectual property.
When those two men began working together, what happened legally?
Did a new company acquire existing rights?
Were patents licensed?
Was new intellectual property developed?
Did Ray contribute technology in exchange for equity?
Did investors purchase interests in the business?
Did Wellbeing eventually become the owner?
Or does another entity still control some of the underlying rights?
At present, I do not have enough documentary evidence to answer those questions conclusively.
That is exactly why they remain part of the investigation.
The Investment Round Makes Ownership More Important
This would already be interesting from a historical perspective.
But Wellbeing's move into investment makes it commercially significant.
Wellbeing announced in 2026 that it had closed the first tranche of an investment round.
For investors considering a biotechnology company, intellectual property can be one of the most valuable assets under consideration.
Wellbeing — First tranche of its 2026 investment round
An investor should reasonably want to know exactly what the company owns.
Not what it developed historically.
Not what its scientists invented.
What does the investment vehicle legally control today?
Questions Any Serious Investor Could Ask
Does Wellbeing own the relevant patents?
If not, who does?
Does Wellbeing operate under a licence?
Is that licence exclusive?
Which countries does it cover?
How long does it last?
Can it be terminated?
Are royalties payable to another company or individual?
Are any patents approaching expiry?
What proprietary technology exists outside the older patent families?
And does the intellectual property actually prevent competitors from producing a similar therapy?
Those are basic biotechnology due-diligence questions.
The 2008 Priority Date Creates a Patent-Life Question
The earliest British priority applications associated with the microvesicle family date to January and March 2008.
Patent duration is legally complex.
Different jurisdictions may have different filing histories.
There may be divisionals, continuations, later inventions, maintenance requirements or other factors affecting individual rights.
Therefore, I am not stating that every patent associated with Ray's technology expires on one specific date.
But the age of the original family makes one question unavoidable:
How much meaningful patent protection remains?
For a company seeking investment in 2026, that could matter considerably.
A Patent Moat Is Not the Same as Scientific Proof
There is another distinction investors and patients should understand.
Strong intellectual property and strong clinical evidence are different assets.
A company can own an excellent patent covering technology that ultimately fails clinically.
Conversely, a clinically useful treatment may have weak patent protection.
So two separate due-diligence questions exist.
Does Wellbeing control valuable intellectual property?
And:
Does robust clinical evidence demonstrate that the treatment works?
One does not answer the other.
What We Can Establish
The investigation has now reached a point where several facts can be stated with reasonable confidence.
Stephen Ray is named as inventor on a microvesicle patent family with British priority claims dating to 2008.
Lydac Neuroscience Limited appears as applicant in the US record.
An official Canadian patent publication identifies Lydac as proprietor or assignee in connection with the same broader family.
Historical material separately connects Stephen Ray with Natural Biosciences SA and reports activity involving regenerative or stem-cell treatment.
Additional patent records associate Ray with earlier biological inventions involving RNA.
And today, Ray is presented by Wellbeing as a senior scientific figure connected with its Cell-Free Therapy.
Those points are documented.
What We Cannot Yet Establish
There are equally important things we cannot yet responsibly claim.
We cannot yet establish that Natural Biosciences acquired Lydac's patents.
We cannot yet establish that Wellbeing directly owns the original microvesicle patent family.
We cannot yet establish the complete assignment or licensing chain.
We cannot assume the patented 2008 technology is identical to the Cell-Free Therapy being delivered today.
And the existence of those patents does not establish that Cell-Free Therapy is clinically effective.
Those distinctions protect the integrity of this investigation.
They also tell us exactly where to look next.
Conclusion: We Found an Earlier Corporate Rights Holder
The question behind this chapter was:
Who owned Stephen Ray's science?
We now have part of the answer.
The patent records establish a documented corporate relationship between Stephen Ray's microvesicle invention and Lydac Neuroscience Limited.
That is significant.
It means the intellectual-property history does not begin with Wellbeing.
And it does not appear to begin with Natural Biosciences either.
There was an earlier corporate structure surrounding the technology.
Now we need to discover what happened to it.
What became of Lydac?
Who controlled it?
Who invested in it?
What happened to its patents?
Did the rights move to another company?
Did Natural Biosciences become involved?
When did Andrew Chancellor enter the commercial structure?
And ultimately:
How did technology associated with Lydac Neuroscience become connected—if it did—to the Cell-Free Therapy being promoted by Wellbeing International Foundation today?
Those questions matter to patients.
They matter to scientists.
But now that Wellbeing is raising investment capital, they matter particularly to investors.
Because before investing in a biotechnology company's future, there is one question that should always be answered about its most valuable scientific asset:
Who actually owns it?
Next: Chapter Seven — What Happened to Lydac Neuroscience?
The patents identify Lydac Neuroscience Limited as an early corporate rights holder associated with Stephen Ray's microvesicle technology. Now the investigation turns to the company itself: its directors, ownership, financial history, eventual fate—and, most importantly, what happened to its intellectual property.
Comments